R2810-ONC-ISA-1981
17 februari 2022
A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after ≥First Line…
Archief
- 1
- 2
HER2CLIMB-02
6 september 2021
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer Protocolnummer: SGNTUC-016 Eudractnummer:…
Destiny-PanTumor02
15 juni 2021
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02) Protocolnummer D967VC00001…
M15-913
12 april 2021
An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies. M15-913 Protocolnummer: M15-913 Eudract nummer: 2016-003887-37 METc…
EORTC 1403 / rEECur
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma Eudractnummer: 2014-000259-99 Dit is een prospectief, multicenter, gerandomiseerd en open-label fase II/fase…
Sunniforecast
A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal…
IMPACT-RCC
Watchful waiting in patients with good and intermediate risk metastatic renal cell carcinoma; an imaging guided observational approach. METcnummer: 2014.176 Onderzoekscode: O126 Samenvatting In een deel van de…
CA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer (CheckMate 901:…
ICRA
ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736) Protocolnummer: ESR-18-13667 EudraCT nummer:…
CA017-078
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or Nivolumab…
Tiger
MOTICA – Longitudinal
Short-term Testosterone Replacement in Testicular Cancer Survivors
Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk; a pilot study. METc nummer: 2017/436 Onderzoekscode: Samenvatting Het vaststellen van de effecten van…
SEA-CAT
Senescence and the early ageing phenotype after chemotherapy for testicular cancer. The SEA-CAT study Protocolnummer: 201700615 Eudractnummer: METc nummer: 2017/483 Onderzoekscode: Samenvatting Het doel van dit project is…
MOTICA – Cross
Vascular fingerprint
Vascular fingerprint
Vascular fingerprint to identify patients at risk for arterial cardiovascular events within the first year after start of cisplatin-based chemotherapy for testicular cancer: a validation study. METc nummer:…
KO-TIP-007
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS…
ImaGelato
Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition? ImaGelato Protocolnummer: 201900180 Eudractnummer: 2019-001197-28 METc nummer: 2019/232 Onderzoekscode:…
SONIA
Endocrine therapy plus CDK 4/6 inhibition in first or second line for hormone receptor positive advanced breast cancer. SONIA. Eudract nummer: 2017-002334-23 METc nummer: 2018/351 Samenvatting Het belangrijkste…